Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 57 entries
Sorted by: Best Match Show Resources per page
Autoimmune-like drug-induced liver injury: a review and update for the clinician.

Expert opinion on drug metabolism & toxicology

Stine JG, Northup PG.
PMID: 27402321
Expert Opin Drug Metab Toxicol. 2016 Nov;12(11):1291-1301. doi: 10.1080/17425255.2016.1211110. Epub 2016 Jul 21.

INTRODUCTION: Autoimmune-like drug-induced liver injury (DI-AIH) is a rare but serious event with a growing body of scientific evidence and a fair degree of uncertainty. Areas covered: This review covers the definition, pathophysiology, treatment and patient-centered outcomes of DI-AIH...

Cite
Stine JG, Northup PG. Autoimmune-like drug-induced liver injury: a review and update for the clinician. Expert Opin Drug Metab Toxicol. 2016;12(11):1291-1301doi: 10.1080/17425255.2016.1211110.
Stine, J. G., & Northup, P. G. (2016). Autoimmune-like drug-induced liver injury: a review and update for the clinician. Expert opinion on drug metabolism & toxicology, 12(11), 1291-1301. https://doi.org/10.1080/17425255.2016.1211110
Stine, Jonathan G, and Northup, Patrick G. "Autoimmune-like drug-induced liver injury: a review and update for the clinician." Expert opinion on drug metabolism & toxicology vol. 12,11 (2016): 1291-1301. doi: https://doi.org/10.1080/17425255.2016.1211110
Stine JG, Northup PG. Autoimmune-like drug-induced liver injury: a review and update for the clinician. Expert Opin Drug Metab Toxicol. 2016 Nov;12(11):1291-1301. doi: 10.1080/17425255.2016.1211110. Epub 2016 Jul 21. PMID: 27402321.
Copy Download .nbib Format: NLM
Erratum.

Expert opinion on drug metabolism & toxicology

[No authors listed]
PMID: 27260105
Expert Opin Drug Metab Toxicol. 2016 Jul;12(7):v. doi: 10.1080/17425255.2016.1197356. Epub 2016 Jun 03.

No abstract available.

Cite
Erratum. Expert Opin Drug Metab Toxicol. 2016;12(7):vdoi: 10.1080/17425255.2016.1197356.
(2016). Erratum. Expert opinion on drug metabolism & toxicology, 12(7), v. https://doi.org/10.1080/17425255.2016.1197356
"Erratum." Expert opinion on drug metabolism & toxicology vol. 12,7 (2016): v. doi: https://doi.org/10.1080/17425255.2016.1197356
Erratum. Expert Opin Drug Metab Toxicol. 2016 Jul;12(7):v. doi: 10.1080/17425255.2016.1197356. Epub 2016 Jun 03. PMID: 27260105.
Copy Download .nbib Format: NLM
Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.

Expert opinion on drug metabolism & toxicology

Bose P, Gandhi VV, Keating MJ.
PMID: 27686109
Expert Opin Drug Metab Toxicol. 2016 Nov;12(11):1381-1392. doi: 10.1080/17425255.2016.1239717. Epub 2016 Oct 11.

INTRODUCTION: Ibrutinib, a first-in-class covalent inhibitor of Bruton's tyrosine kinase (BTK), is approved in many countries for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) and for previously untreated disease with a 17p deletion and, most recently, as a...

Cite
Bose P, Gandhi VV, Keating MJ. Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. Expert Opin Drug Metab Toxicol. 2016;12(11):1381-1392doi: 10.1080/17425255.2016.1239717.
Bose, P., Gandhi, V. V., & Keating, M. J. (2016). Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. Expert opinion on drug metabolism & toxicology, 12(11), 1381-1392. https://doi.org/10.1080/17425255.2016.1239717
Bose, Prithviraj, et al. "Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses." Expert opinion on drug metabolism & toxicology vol. 12,11 (2016): 1381-1392. doi: https://doi.org/10.1080/17425255.2016.1239717
Bose P, Gandhi VV, Keating MJ. Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. Expert Opin Drug Metab Toxicol. 2016 Nov;12(11):1381-1392. doi: 10.1080/17425255.2016.1239717. Epub 2016 Oct 11. PMID: 27686109; PMCID: PMC5391303.
Copy Download .nbib Format: NLM
The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients.

Expert opinion on drug metabolism & toxicology

Tverdohleb T, Dinc B, Knezevic I, Candido KD, Knezevic NN.
PMID: 27388970
Expert Opin Drug Metab Toxicol. 2016 Nov;12(11):1303-1311. doi: 10.1080/17425255.2016.1209482. Epub 2016 Jul 15.

INTRODUCTION: Pharmacogenomics is the field that studies an individualized treatment approach for patients' medication regimen that can impact drug safety, productivity, and personalized health care. Pharmacogenomics characterizes the genetic differences in metabolic pathways which can affect a patient's individual...

Cite
Tverdohleb T, Dinc B, Knezevic I, et al. The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients. Expert Opin Drug Metab Toxicol. 2016;12(11):1303-1311doi: 10.1080/17425255.2016.1209482.
Tverdohleb, T., Dinc, B., Knezevic, I., Candido, K. D., & Knezevic, N. N. (2016). The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients. Expert opinion on drug metabolism & toxicology, 12(11), 1303-1311. https://doi.org/10.1080/17425255.2016.1209482
Tverdohleb, Tatiana, et al. "The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients." Expert opinion on drug metabolism & toxicology vol. 12,11 (2016): 1303-1311. doi: https://doi.org/10.1080/17425255.2016.1209482
Tverdohleb T, Dinc B, Knezevic I, Candido KD, Knezevic NN. The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients. Expert Opin Drug Metab Toxicol. 2016 Nov;12(11):1303-1311. doi: 10.1080/17425255.2016.1209482. Epub 2016 Jul 15. PMID: 27388970.
Copy Download .nbib Format: NLM
Prediction and management of drug reaction with eosinophilia and systemic symptoms (DRESS).

Expert opinion on drug metabolism & toxicology

Shiohara T, Kano Y, Hirahara K, Aoyama Y.
PMID: 28633581
Expert Opin Drug Metab Toxicol. 2017 Jul;13(7):701-704. doi: 10.1080/17425255.2017.1297422. Epub 2017 Mar 01.

No abstract available.

Cite
Shiohara T, Kano Y, Hirahara K, et al. Prediction and management of drug reaction with eosinophilia and systemic symptoms (DRESS). Expert Opin Drug Metab Toxicol. 2017;13(7):701-704doi: 10.1080/17425255.2017.1297422.
Shiohara, T., Kano, Y., Hirahara, K., & Aoyama, Y. (2017). Prediction and management of drug reaction with eosinophilia and systemic symptoms (DRESS). Expert opinion on drug metabolism & toxicology, 13(7), 701-704. https://doi.org/10.1080/17425255.2017.1297422
Shiohara, Tetsuo, et al. "Prediction and management of drug reaction with eosinophilia and systemic symptoms (DRESS)." Expert opinion on drug metabolism & toxicology vol. 13,7 (2017): 701-704. doi: https://doi.org/10.1080/17425255.2017.1297422
Shiohara T, Kano Y, Hirahara K, Aoyama Y. Prediction and management of drug reaction with eosinophilia and systemic symptoms (DRESS). Expert Opin Drug Metab Toxicol. 2017 Jul;13(7):701-704. doi: 10.1080/17425255.2017.1297422. Epub 2017 Mar 01. PMID: 28633581.
Copy Download .nbib Format: NLM
Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK).

Expert opinion on drug metabolism & toxicology

Aguayo Bonniard A, Yeung JY, Chan CC, Birt CM.
PMID: 27398637
Expert Opin Drug Metab Toxicol. 2016 Nov;12(11):1279-1289. doi: 10.1080/17425255.2016.1209481. Epub 2016 Jul 18.

INTRODUCTION: This review discusses the evidence concerning the effect of topical medications and their preservatives on the ocular surface in glaucoma patients. The role of topical anti-glaucoma medication remains critical in the management of chronic glaucoma worldwide but the...

Cite
Aguayo Bonniard A, Yeung JY, Chan CC, et al. Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK). Expert Opin Drug Metab Toxicol. 2016;12(11):1279-1289doi: 10.1080/17425255.2016.1209481.
Aguayo Bonniard, A., Yeung, J. Y., Chan, C. C., & Birt, C. M. (2016). Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK). Expert opinion on drug metabolism & toxicology, 12(11), 1279-1289. https://doi.org/10.1080/17425255.2016.1209481
Aguayo Bonniard, Alberto, et al. "Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK)." Expert opinion on drug metabolism & toxicology vol. 12,11 (2016): 1279-1289. doi: https://doi.org/10.1080/17425255.2016.1209481
Aguayo Bonniard A, Yeung JY, Chan CC, Birt CM. Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK). Expert Opin Drug Metab Toxicol. 2016 Nov;12(11):1279-1289. doi: 10.1080/17425255.2016.1209481. Epub 2016 Jul 18. PMID: 27398637.
Copy Download .nbib Format: NLM
Correction.

Expert opinion on drug metabolism & toxicology

[No authors listed]
PMID: 31037977
Expert Opin Drug Metab Toxicol. 2019 Jun;15(6):521. doi: 10.1080/17425255.2019.1611819. Epub 2019 Apr 30.

No abstract available.

Cite
Correction. Expert Opin Drug Metab Toxicol. 2019;15(6):521doi: 10.1080/17425255.2019.1611819.
(2019). Correction. Expert opinion on drug metabolism & toxicology, 15(6), 521. https://doi.org/10.1080/17425255.2019.1611819
"Correction." Expert opinion on drug metabolism & toxicology vol. 15,6 (2019): 521. doi: https://doi.org/10.1080/17425255.2019.1611819
Correction. Expert Opin Drug Metab Toxicol. 2019 Jun;15(6):521. doi: 10.1080/17425255.2019.1611819. Epub 2019 Apr 30. PMID: 31037977.
Copy Download .nbib Format: NLM
Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease.

Expert opinion on drug metabolism & toxicology

Deben DS, Wong DR, van Bodegraven AA.
PMID: 35023443
Expert Opin Drug Metab Toxicol. 2022 Jan 13; doi: 10.1080/17425255.2021.2029406. Epub 2022 Jan 13.

INTRODUCTION: Despite new treatment options for inflammatory bowel disease (IBD), conventional thiopurines remain a common treatment option for maintaining remission, particularly in non-Westernized countries. Therapeutic drug monitoring (TDM) is advised in standard care for optimizing therapy strategies to improve...

Cite
Deben DS, Wong DR, van Bodegraven AA. Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease. Expert Opin Drug Metab Toxicol. 2022;doi: 10.1080/17425255.2021.2029406.
Deben, D. S., Wong, D. R., & van Bodegraven, A. A. (2022). Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease. Expert opinion on drug metabolism & toxicology, . https://doi.org/10.1080/17425255.2021.2029406
Deben, Debbie S, et al. "Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease." Expert opinion on drug metabolism & toxicology vol. (2022). doi: https://doi.org/10.1080/17425255.2021.2029406
Deben DS, Wong DR, van Bodegraven AA. Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease. Expert Opin Drug Metab Toxicol. 2022 Jan 13; doi: 10.1080/17425255.2021.2029406. Epub 2022 Jan 13. PMID: 35023443.
Copy Download .nbib Format: NLM
Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies.

Expert opinion on drug metabolism & toxicology

Papamichael K, Cheifetz AS.
PMID: 34996330
Expert Opin Drug Metab Toxicol. 2022 Jan 07; doi: 10.1080/17425255.2021.2027367. Epub 2022 Jan 07.

INTRODUCTION: Therapeutic drug monitoring (TDM) is useful for optimizing monoclonal antibodies (mAbs) for the treatment of immune-mediated inflammatory disorders including inflammatory bowel disease (IBD). However, TDM in clinical practice is still restricted by long turnaround times between sampling and...

Cite
Papamichael K, Cheifetz AS. Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies. Expert Opin Drug Metab Toxicol. 2022;doi: 10.1080/17425255.2021.2027367.
Papamichael, K., & Cheifetz, A. S. (2022). Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies. Expert opinion on drug metabolism & toxicology, . https://doi.org/10.1080/17425255.2021.2027367
Papamichael, Konstantinos, and Cheifetz, Adam S. "Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies." Expert opinion on drug metabolism & toxicology vol. (2022). doi: https://doi.org/10.1080/17425255.2021.2027367
Papamichael K, Cheifetz AS. Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies. Expert Opin Drug Metab Toxicol. 2022 Jan 07; doi: 10.1080/17425255.2021.2027367. Epub 2022 Jan 07. PMID: 34996330.
Copy Download .nbib Format: NLM
Novel models for the prediction of drug-gene interactions.

Expert opinion on drug metabolism & toxicology

Türk D, Fuhr LM, Marok FZ, Rüdesheim S, Kühn A, Selzer D, Schwab M, Lehr T.
PMID: 34727800
Expert Opin Drug Metab Toxicol. 2021 Nov;17(11):1293-1310. doi: 10.1080/17425255.2021.1998455. Epub 2021 Nov 15.

INTRODUCTION: Adverse drug reactions (ADRs) are among the leading causes of death, and frequently associated with drug-gene interactions (DGIs). In addition to pharmacogenomic programs for implementation of genetic preemptive testing into clinical practice, mathematical modeling can help to understand,...

Cite
Türk D, Fuhr LM, Marok FZ, et al. Novel models for the prediction of drug-gene interactions. Expert Opin Drug Metab Toxicol. 2021;17(11):1293-1310doi: 10.1080/17425255.2021.1998455.
Türk, D., Fuhr, L. M., Marok, F. Z., Rüdesheim, S., Kühn, A., Selzer, D., Schwab, M., & Lehr, T. (2021). Novel models for the prediction of drug-gene interactions. Expert opinion on drug metabolism & toxicology, 17(11), 1293-1310. https://doi.org/10.1080/17425255.2021.1998455
Türk, Denise, et al. "Novel models for the prediction of drug-gene interactions." Expert opinion on drug metabolism & toxicology vol. 17,11 (2021): 1293-1310. doi: https://doi.org/10.1080/17425255.2021.1998455
Türk D, Fuhr LM, Marok FZ, Rüdesheim S, Kühn A, Selzer D, Schwab M, Lehr T. Novel models for the prediction of drug-gene interactions. Expert Opin Drug Metab Toxicol. 2021 Nov;17(11):1293-1310. doi: 10.1080/17425255.2021.1998455. Epub 2021 Nov 15. PMID: 34727800.
Copy Download .nbib Format: NLM
A Quantitative Approach to the Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 2C8 Inhibition.

Expert opinion on drug metabolism & toxicology

Di Paolo V, Ferrari FM, Poggesi I, Quintieri L.
PMID: 34720033
Expert Opin Drug Metab Toxicol. 2021 Nov;17(11):1345-1352. doi: 10.1080/17425255.2021.1998453. Epub 2021 Nov 02.

BACKGROUND: Ohno and Colleagues proposed an approach for predicting drug-drug interactions (DDIs) mediated by cytochrome P450 (CYP) 3A4 based on the use of the ratio of the inhibited to non-inhibited area under the plasma concentration time curve (AUC) of...

Cite
Di Paolo V, Ferrari FM, Poggesi I, et al. A Quantitative Approach to the Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 2C8 Inhibition. Expert Opin Drug Metab Toxicol. 2021;17(11):1345-1352doi: 10.1080/17425255.2021.1998453.
Di Paolo, V., Ferrari, F. M., Poggesi, I., & Quintieri, L. (2021). A Quantitative Approach to the Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 2C8 Inhibition. Expert opinion on drug metabolism & toxicology, 17(11), 1345-1352. https://doi.org/10.1080/17425255.2021.1998453
Di Paolo, Veronica, et al. "A Quantitative Approach to the Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 2C8 Inhibition." Expert opinion on drug metabolism & toxicology vol. 17,11 (2021): 1345-1352. doi: https://doi.org/10.1080/17425255.2021.1998453
Di Paolo V, Ferrari FM, Poggesi I, Quintieri L. A Quantitative Approach to the Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 2C8 Inhibition. Expert Opin Drug Metab Toxicol. 2021 Nov;17(11):1345-1352. doi: 10.1080/17425255.2021.1998453. Epub 2021 Nov 02. PMID: 34720033.
Copy Download .nbib Format: NLM
Machine learning models in the prediction of drug metabolism: challenges and future perspectives.

Expert opinion on drug metabolism & toxicology

Litsa EE, Das P, Kavraki LE.
PMID: 34706606
Expert Opin Drug Metab Toxicol. 2021 Nov;17(11):1245-1247. doi: 10.1080/17425255.2021.1998454. Epub 2021 Nov 02.

No abstract available.

Cite
Litsa EE, Das P, Kavraki LE. Machine learning models in the prediction of drug metabolism: challenges and future perspectives. Expert Opin Drug Metab Toxicol. 2021;17(11):1245-1247doi: 10.1080/17425255.2021.1998454.
Litsa, E. E., Das, P., & Kavraki, L. E. (2021). Machine learning models in the prediction of drug metabolism: challenges and future perspectives. Expert opinion on drug metabolism & toxicology, 17(11), 1245-1247. https://doi.org/10.1080/17425255.2021.1998454
Litsa, Eleni E, et al. "Machine learning models in the prediction of drug metabolism: challenges and future perspectives." Expert opinion on drug metabolism & toxicology vol. 17,11 (2021): 1245-1247. doi: https://doi.org/10.1080/17425255.2021.1998454
Litsa EE, Das P, Kavraki LE. Machine learning models in the prediction of drug metabolism: challenges and future perspectives. Expert Opin Drug Metab Toxicol. 2021 Nov;17(11):1245-1247. doi: 10.1080/17425255.2021.1998454. Epub 2021 Nov 02. PMID: 34706606.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 57 entries